The vaccine generated an immune response in a study of roughly 1,000 patients, and all of the side effects were deemed mild or moderate.
The UK has secured early access to 90 million doses of promising coronavirus vaccine candidates.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
Sovereign fund leads UK Glympse Bio's $46.7m fundraising
(Bloomberg) -- Sanofi is studying potential acquisitions of U.S. biotechnology companies including Principia Biopharma Inc. as it seeks innovative treatments for clinical areas including ...
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020.
It has nearly been ten years since the Supreme Court’s landmark Mayo v. Prometheus (132 S.Ct. 1289 (2012)) decision, in which the Court established a...